3Alan F, Catherine S, John G, et al, Phase Ⅰ/Ⅱ trial of cyclosporine as chemotherapy-resistance modifier in acute leukemia[J]. J Clin Oncol , 1993,11:1652
4Stein U, Walther W, Shoemaker R H. Modulation of mdrl expression by cytokines in human colon carcinoma cell: an approach for reversal of multidrug resistance[J]. Cancer, 1996,74:1384
5Mutsushita H, Kizaki M, Kobuynshi H,et al. Restoration of retinoid seneitivity by MDR ribozy mes in retinoic acid-resistant myeloid leukemia cell[J]. Blood, 1998,91 (7) : 2452
6Kobuynshi H, Takemum Y, Wang F S, et al, Retrovirus medinted transfer of anti-MDR1 ham merhead ribozy mes into multidrug resistant human leukemia cell ;screening for effective target sites[J]. Int J Cancer, 1999,8 (6): 9 44
7Motomuras, Metoji T, Takunashi M, et al, Inhibition of Pglyeoprotein and recovery of drug sensitivity of human acute leukemia blasts cell by multidrug resistance gene (mdr1)antisense oligonucleotides [J ]. Blood, 1998,91 (9): 3163
8Sola J E, Colombani P M. Modulation of resistance with antisense oligonucleotides to mdr1 mRNA[J]. Am Surg Oncol, 1996,3 (1):80
9Cocca C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in human leukemia resistant cell line by mdr1 antisense oligonucleotides [J]. Cancer Res, 1996,56 (19): 4332
4Hiddemann W. Proposal for the classification of relapsed and refractory acute myeloid leukemias the basis for and age adjusted randomized comparison of sequentially apphed high-close versus intermediate cytosin arabinoside in combination with mitoxantrone (S-HAM).Hematol and Blood Transfusion, 1990,33:604-608.
5Alan F, Catherine S, John G, et al. Phase Ⅰ/Ⅱ trial of cyclosporine as a chemotherapy- resistance modifier in acute leukemia. J Clin Oncol, 1993, 11 : 1652- 1656.
6Stein U, Walther W, Shoemaker R H. Modulation of mdrl expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.Cancer, 1996,74 :1384- 1388.
7Aquerretu Z,Aldaz A,Giraldez J,et al.Pharmacodynamics of high-dose methotrexate in pediatric patients[J].Ann Pharmacother,2002,36 (9):1344.
8Kagawa Y,Mukohara R,Hori H,et al.Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high dose of cancer chemotherapy[J].Cancer Chemother Pharmacol,2004,54 (1):34.
9Hempel L,Misselwitz J,Fleck C,et al.Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function[J].Med Pediatric Oncol,2003,40 (6):348.
10Schmidt-WolfI G H, Lefterovap, Johnston V, et al. Sensitivity of muhidrug resistant tumor cell lines to immunologic effector cells[J]. Cell Immunol,1996,169(1):85-90.
